Another year, another set of blockbuster year-end results from the three most talked about companies in psychedelics. Mind Medicine (MNMD), Compass Pathways (CMPS), and atai Life Sciences (ATAI) have all greatly benefited from 2021’s banner year. With a handful of successful funding rounds, strategic partnerships, and their continuous push for drug development, the “Big 3” have had a resounding impact on investor awareness and the entire industry in general.
But with stock prices recently underperforming, many are wondering what’s next? And more importantly, what exactly is there to look forward to?
Given that each company has officially reported its 2021 year-end financial results, it’s time to look at the numbers.
In this week’s video breakdown, Psychedelic Invest’s Adam Tubero gives us a closer look at company earnings and their leading drug candidates to further draw comparisons and provide timely insight on which company is best positioned for growth.